{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-259302","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.046197+00:00","generated_at":"2026-05-17T01:07:16.638045+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"4D Molecular Therapeutics (FDMT) signs $85M upfront license deal with Otsuka for 4D-150 in APAC","bullets":["Upfront cash payment of $85M from Otsuka; additional cost sharing of at least $50M over next three years.","Potential regulatory and commercial milestones up to $335.5M, plus tiered double-digit royalties on net sales in APAC.","Otsuka gains exclusive rights to develop and commercialize 4D-150 for wet AMD and DME in Japan, China, Australia, and other APAC markets.","Phase 3 study 4FRONT-1 enrollment exceeds expectations: over 200 patients randomized as of Oct 30, 2025.","FDMT retains full rights outside APAC, including US, Latin America, and Europe."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-259302","json":"https://secwatch.observer/filing/0001193125-25-259302.json","markdown":"https://secwatch.observer/filing/0001193125-25-259302.md","text":"https://secwatch.observer/filing/0001193125-25-259302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525259302/0001193125-25-259302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525259302/d41653d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:07:16.638045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}